Hong Kong Stock Movement: LEE'S PHARM surged 22.89%

Hong Kong Stock Movement Stocks with High Trading Volume in the Industry Stone Pharmaceutical Group rose 3.00%. Based on recent important news: On September 12, Stone Pharmaceutical Group announced that its developed SYH2066 tablets were approved by the National Medical Products Administration to conduct clinical trials in China. This drug is a Class 1 new chemical drug targeting respiratory syncytial virus, with high clinical development value, driving the stock price up. Data source: Zhitong Finance. On September 12, the new drug application for KN026, developed in collaboration with CanSino Biologics, was accepted by the National Medical Products Administration. This drug is used for the treatment of HER2-positive gastric cancer, with clinical trials showing significant efficacy and high safety, further enhancing market confidence. Data source: Times Finance. On September 12, Stone Pharmaceutical Group announced that investment banks rated its stock mainly as a buy, with a target average price of HKD 12.71, boosting investor confidence. Data source: Stone Pharmaceutical Group announcement. The innovative drug industry is recovering, driven by clinical data. Fosun Pharma rose 5.58%. According to recent important news: On September 14, Fosun Pharma adjusted its profit forecast; although the expected operating income was lowered, the net profit attributable to the parent company was raised, indicating enhanced profitability, driving the stock price up. Data source: Company announcement. Stocks with High Market Capitalization in the Industry Hengrui Medicine rose 1.68%. Based on recent important news: On September 12, UBS Group increased its holdings in Hengrui Medicine, raising its shareholding ratio to 7.04%, driving the stock price up. Data source: Zhitong Finance. On September 15, Hengrui Medicine expects multiple innovative drug projects to be approved for listing in the next two years, with strong R&D capabilities, enhancing market confidence. Data source: Securities Star. On September 12, Hengrui's innovative drug sales revenue grew significantly, with external licensing of innovative drugs becoming a new engine for performance growth. Data source: Zhitong Finance. Industry policy risk affects expectations